Wendy Levin
AstraZeneca
3 Papers
3 Citations
Wendy Levin is an academic researcher from AstraZeneca. The author has contributed to research in topics: Durvalumab & Tremelimumab. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Thomas Powles,Michiel S. van der Heijden,Daniel Castellano,Matthew D. Galsky,Yohann Loriot,Daniel P. Petrylak,Osamu Ogawa,Se Hoon Park,Jae-Lyun Lee,Ugo De Giorgi,Martin Bögemann,Aristotelis Bamias,Bernhard J. Eigl,Howard Gurney,Som D. Mukherjee,Yves Fradet,Iwona Skoneczna,Marinos Tsiatas,Andrey Novikov,Cristina Suarez,Andre P. Fay,Ignacio Duran,Andrea Necchi,Sophie Wildsmith,Philip He,Natasha Angra,Ashok K. Gupta,Wendy Levin,Joaquim Bellmunt,Jae-Lyun Lee,Hans Westgeest,Aude Flechon,Yen-Chuan Ou,Inkeun Park,Vsevolod Matveev,Begoña Perez-Valderrama,Susanna Cheng,Stephen Jay Frank,Urbano Anido,Alketa Hamzaj,Margitta Retz,Srikala S. Sridhar,Giorgio V. Scagliotti,Jens Voortman,Boris Alekseev,Anna Alyasova,Boris Komyakov,Herlinde Dumez,Michel Pavic,Go Kimura,Atsushi Mizokami,Susanne Osanto,Jose Angel Arranz,Djura Piersma,Sang Joon Shin,Oleg Karyakin,Ignacio Delgado,Jose Luis Gonzalez,See-Tong Pang,Anna Tran,Oleg Lipatov,Wen Pin Su,Thomas W. Flaig,Ajjai Alva,Hwa Park Kyong,Evgeny Kopyltsov,Elena Almagro,Monserrat Domenech,Yen-Hwa Chang,Brieuc Sautois,Andre Ravaux,Gerasimos Aravantinos,Vasileios Georgoulias,Sasja Mulder,Yu Jung Kim,Fabio Kater,Christine Chevreau,Scott T. Tagawa,Pawel Zalewski,Florence Joly,Gencay Hatiboglu,Luca Gianni,Franco Morelli,Rosa Tambaro,Yasuhiro Hashimoto,Alexander Nosov,Albert Font,Alejo Rodriguez-Vida,Robert Jones,Naveen S. Vasudev,Sandhya Srinivas,Jingsong Zhang,Thierry Gil,Daygen Finch,Marc-Oliver Grimm,Yu-Li Su,Simon Chowdhury,Christopher Hocking,Eugen Plas,Scott North,Niels Viggo Jensen,Christine Theodore,Florian Imkamp,Avivit Peer,Takashi Kobayashi,Hideki Sakai,Naoto Sassa,Kazuhiro Yoshimura,Maureen J.B. Aarts,Ana Ferreira Castro,Marlen Topuzov,Juan Francisco Rodriguez,Federico Vazquez,Yu-Chieh Tsai,Simon J. Crabb,Syed A. Hussain,Johanna C. Bendell,Marine Gross-Goupil,Gravis Gwenaelle,Raanan Berger,Galina Statsenko,Linda Evans,Alexandra Drakaki,Bradley Somer,Ian D. Davis,James Lynam,Giuliano Santos Borges,Aldo Dettino,Graziella Martins,Luis Eduardo Zucca,Mads Agerbæk,Haralambos Kalofonos,Eli Rosenbaum,Hideki Enokida,Hiroaki Kikukawa,Kazuo Nishimura,Satoshi Tamada,Motohide Uemura,Yamil Lopez,Jourik A. Gietema,Marcin Slojewski,Isabel Fernandes,Alexey Smolin,Danish Mazhar,Arash Rezazadeh Kalebasty,Bradley Carthon,Wolfgang Loidl,Fabio Franke,Gustavo Girotto,Nimira S. Alimohamed,Robyn Macfarlane,Helle Pappot,Guenter Niegisch,Dimitrios Mavroudis,Avishay Sella,Camillo Porta,Shin Ebara,Motonobu Nakamura,Wataru Obara,Norihiko Okuno,Nobuo Shinohara,Mikio Sugimoto,Akitaka Suzuki,Noriaki Tokuda,Hiroji Uemura,Akito Yamaguchi,Francisco Ramirez,Pawel Rozanowski,Paweł Wiechno,Bhumsuk Keam,Nikolay Kislov,Denis Plaksin,Irfan Cicin,Satish Kumar,Joseph Rosales,Ulka N. Vaishampayan,Stéphane Culine,Christos Papandreou,Taketoshi Nara,Mustafa Erman,Laurence Kreiger,Juliana Janoski,Diogo Rosa,Mariana Siqueira,Christina Canil,Lisa Sengeløv,Jean-Marc Tourani,Gaku Arai,Katsuyoshi Hashine,Mutsushi Kawakita,Noboru Nakaigawa,Hayahito Nomi,Hiroaki Shiina,Hiroyoshi Suzuki,Junji Yonese,Roberto Kuri,Eleazar Macedo,Samuel Rivera,Alberto Villalobos Prieto,Anna Polakiewicz-Gilowska,Renata Zaucha,Fabio Lopes,Roman Ponomarev,Mark Pomerantz,Shahrokh F. Shariat,Cynthia Luk,Krzysztof Lesniewski-Kmak +206 more
TL;DR: The overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or without tremelimumab ( a CTLA-4 inhibitor), as a first-line treatment for metastatic urothelial carcinoma was assessed.
467
697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)
Thomas Powles,M.S. van der Heijden,D. Castellano Gauna,Yohann Loriot,Matthew D. Galsky,Daniel P. Petrylak,Osamu Ogawa,S.H. Park,Andrea Necchi,J-L. Lee,U. De Giorgi,Martin Bögemann,Aristotle Bamias,Andre P. Fay,Ignacio Duran,Natasha Angra,Ashok K. Gupta,Philip He,Wendy Levin,Joaquim Bellmunt +19 more
20
285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC)
S.H. Park,Daniel Castellano,Daniel P. Petrylak,Matthew D. Galsky,M.S. van der Heijden,Yohann Loriot,Osamu Ogawa,W-C Su,W. Huang,Wendy Levin,Salvatore Ferro,Yong Ben,Joaquim Bellmunt,Thomas Powles +13 more
3